Actively Recruiting
Embolization for Meningioma
Led by St. Olavs Hospital · Updated on 2025-06-05
30
Participants Needed
1
Research Sites
772 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma
CONDITIONS
Official Title
Embolization for Meningioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Radiological diagnosis of typical intracranial meningioma with homogenous contrast enhancement or dural attachment
- Indication for treatment due to tumor growth, symptoms, or both
- Tumor location suggesting vascular supply via middle meningeal artery branches
- Age 18 years or older
- Karnofsky performance status of 90 or better (able to carry on normal activity and work)
You will not qualify if you...
- Unable to give informed consent (e.g., due to language barriers, aphasia, or cognitive impairment)
- Previous treatment for meningioma
- Intraosseous tumor growth
- Tumor-related brain swelling (edema)
- Diagnosis of neurofibromatosis type 2
- Presence of systemic cancer
- History of epilepsy
- Progressive neurodegenerative disorders such as multiple sclerosis or Parkinson's disease
- History of psychiatric disorder
- Deemed unfit for participation for any reason by the physician
- Contraindications to MRI
- Allergy to contrast agents
- Relative contraindications to endovascular treatment based on CT angiography findings (e.g., tortuous carotid arteries, carotid stenosis, calcified aortic arch, vascular anomalies increasing treatment risk)
- Digital subtraction angiography showing significant tumor blood supply from vessels other than the middle meningeal artery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St Olavs Hospital
Trondheim, Norway, 7006
Actively Recruiting
Research Team
O
Ole Solheim, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here